Rubius Therapeutics Inc. Stock News

Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 in Advanced Solid Tumors to be Presented in a Poster at the American Association of Cancer Research Annual Meeting on Tuesday, April

Rubius Therapeutics press release (RUBY): Q4 GAAP EPS of -$0.61 misses by $0.02.As of December 31, 2021, cash and cash equivalents were $225.8M as compared to $176.3M in cash,…

First Patient Dosed in Phase 1/2 Clinical Trial of RTX-224 in Patients with Certain Advanced Solid Tumors in January 2022 Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors Continues with No Dose-Limiting Toxicities Observed to Date and an NK Cell Dose Response. Clinical Results Expected in Q1’22

CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report fourth quarter and full year 2021 financial results on Friday, February 25, 2022, before market open.

CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an e

Rubius Therapeutics (RUBY) said the first patient was dosed in its phase 1/2 trial of RTX-224 to treat patients with certain relapsed/refractory or locally advanced solid tumors,

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an e

Rubius Therapeutics Inc (RUBY) shares closed today 15.5% lower than it did at the end of yesterday. The stock is currently up 65.7% year-to-date, up 68.0% over the past 12 months, and down 48.1% over the past five years. Today, the Dow Jones Industrial Average fell 1.2%, and the S&P 500 fell 1.1%. Trading Activity Shares traded as high as $13.48 and as low as $10.61 this week.Shares closed 72.5% below its 52-week high and 57.5% above its 52-week low.Trading volume this week was 131.1% higher than the 10-day average and 286.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -315.2% The company's stock price performance over the past 12 months beats the peer average by -315.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Wall Street analysts predict that Rubius Therapeutics, Inc. (NASDAQ:RUBY) will announce earnings per share of ($0.58) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Rubius Therapeutics earnings. The highest EPS estimate is ($0.55) and the lowest is ($0.61). Rubius Therapeutics posted earnings per share of ($0.50) in the same []

Brokerages predict that Rubius Therapeutics, Inc. (NASDAQ:RUBY) will report earnings per share of ($0.58) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Rubius Therapeutics earnings. The highest EPS estimate is ($0.55) and the lowest is ($0.61). Rubius Therapeutics reported earnings per share of ($0.50) in the same quarter last year, []

Rubius Therapeutics (NASDAQ:RUBY) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Valuation and Earnings This table compares Rubius Therapeutics and Outlook Therapeutics revenue, earnings per share []

Highly Versatile and Programmable RED PLATFORM Enables Multiple Modalities to Target Different Immune Pathways Across a Range of Diseases

Los Angeles, USA, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight There are approximately 15+ key companies developing the Phenylketonuria therapies. In the upcoming years, many new products such as CNSA-001/PTC923 (PTC Therapeutics), HMI-102 (Homology Medicines), and SYNB1618 (Synlogic) are also expected to enter the Phenylketonuria market. PTC-923 is expected to be the most promising drug among all the upcoming therapies. DelveInsight''s " Phenylketonuria Pipeline Insight " report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Phenylketonuria pipeline landscapes. It comprises Phenylketonuria pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Phenylketonuria therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Phenylketonuria pipeline products. Some of the key takeaways from the Phenylketonuria Pipeline Report Major companies such as Synlogic, Homology Medicines, PTC therapeutics, Rubius Therapeutics, NestlÃ, BioMarin, SOM Biotech, Evox Therapeutics, Moderna Therapeutics, Orpharma, Generation Bio, Erydel, Janana therapeutics, American gene technologies, Applied Pharma Research and others are developing potential drug candidates to improve the Phenylketonuria treatment scenario.

In last trading session, Rubius Therapeutics Inc. (NASDAQ:RUBY) saw 1.24 million shares changing hands with its beta currently measuring 2.37. Company’s recent per share price level of $11.86 trading at -$0.5 or -4.05% at ring of the bell on the day assigns it a market valuation of $1.07B. That closing price of RUBY’s stock is … Rubius Therapeutics Inc. (NASDAQ:RUBY) Has Recovered 80.79% To Date, But An Additional -226.39% Is Possible. Read More »